Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two PEG-rhGH Preparations in Healthy Adults
NCT06797505Phase 1Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of peg-somatropin in growth hormone deficiency (GHD) (3 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Peak Plasma Concentration, Area Under the Concentration-Time Curve from Time Zero to Infinity and 1 more. Started Feb 2025; status: completed.
02
Drugs
peg-somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT06797505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797505.